The U.S. Food and Drug Administration (FDA) continues its review of tobacco products to determine if manufacturers can claim them to be modified-risk or reduced-risk as compared to traditional combustible cigarettes. The next study will focus on a line of snus products from Winston-Salem, N.C.-based R.J. Reynolds Tobacco Co., coming up for review by an FDA committee.
The Tobacco Products Scientific Advisory Committee (TPSAC) plays a role in helping the FDA come to its final conclusion on modified risk tobacco product (MRTP) applications that manufacturers put before the agency.
Here’s a breakdown of the role TPSAC plays in how the FDA makes its conclusions with regard to MRTP applications.
Photo illustration by CSP